Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

The GH Secretagogues Market

Ipamorelin, CJC-1295, Sermorelin, Tesamorelin, MK-677

Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Mostly unapproved; sermorelin and tesamorelin have FDA histories, others do not

Reference only. Not medical advice.

What can go wrong

Raising GH/IGF-1 can cause water retention, joint pain, carpal tunnel symptoms, and insulin resistance/elevated blood glucose. The theoretical concern that sustained IGF-1 elevation could promote tumor growth is unresolved. Most products in this category are compounded or sold as gray-market 'research chemicals' of unverified purity, adding contamination and dosing risks.

This is something to take to a clinician. The Atlas can tell you what is known about the gh secretagogues market in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

Growth hormone (GH) secretagogues are compounds that prompt the pituitary to release the body's own GH, rather than injecting GH directly. The category spans GHRH analogs (sermorelin, CJC-1295, tesamorelin) and ghrelin-receptor agonists (ipamorelin, GHRP-2/6, and the oral non-peptide MK-677/ibutamoren). They are a mainstay of anti-aging and longevity clinics, but the regulatory and evidence picture varies enormously across members, from FDA-approved (tesamorelin) to never-approved research chemicals (MK-677, ipamorelin).

The anti-aging clinic's favorite category, big claims, thin evidence for most members.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Anti-aging / 'longevity' (off-label, unproven)
  • Body composition and recovery (off-label)
  • Sleep and 'wellness' claims (off-label)
  • Diagnostic GH stimulation (sermorelin historically)

How it is supposed to work

GHRH analogs (sermorelin, CJC-1295, tesamorelin) bind pituitary GHRH receptors to stimulate pulsatile GH release. Ghrelin-receptor agonists (ipamorelin, MK-677) act at the GHS-R to stimulate GH through a complementary pathway and are often stacked with a GHRH analog. Because they work through the pituitary, proponents argue they preserve more physiologic, pulsatile GH release than exogenous GH.

Evidence is uneven and mostly preclinical

MK-677 has the most human data of the unapproved members, including the 2-year Nass trial, yet that very trial showed increased fasting glucose and reduced insulin sensitivity, and no improvement in strength or function. Ipamorelin, GHRP-6, and GHRP-2 are characterized largely in animal models. Raising GH/IGF-1 is not a proven anti-aging strategy; a 2008 JAMA commentary warned of the absence of robust anti-aging evidence alongside real risks.

Safety in detail

These compounds alter the GH/IGF-1 axis and require physician evaluation and monitoring. Most are not FDA-approved for the uses they are sold for; gray-market versions of unverified purity carry additional documented risks.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • IGF-1
  • Fasting glucose / HbA1c
  • Symptoms of fluid retention / carpal tunnel
  • Blood pressure

What people get wrong

  • Often saidGH secretagogues are a safe, natural anti-aging therapy

    ActuallyMost are unapproved, evidence for anti-aging benefit is absent, and raising GH/IGF-1 carries metabolic and theoretical oncologic risks.

  • Often saidThey are FDA-approved peptides

    ActuallyOnly sermorelin (historically) and tesamorelin are FDA-approved, and for specific indications, not for anti-aging. Ipamorelin, CJC-1295, and MK-677 are not approved for human use.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

At a glance

Sermorelin
GHRH analog; FDA-approved 1997 for pediatric GH deficiency, branded product later discontinued
Tesamorelin
GHRH analog; FDA-approved 2010 for HIV lipodystrophy
CJC-1295 / Ipamorelin
Not FDA-approved; popular compounded/gray-market stack
MK-677 (ibutamoren)
Oral ghrelin mimetic; never FDA-approved for human use

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about The GH Secretagogues Market. A short entry is not a safe entry.

  • Timeline. We have not built the dated record of research and regulatory events.
  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • Nass et al., MK-677 in older adults (Ann Intern Med)2008

    2-year RCT: raised IGF-1 (~84% vs ~17% placebo) and fat-free mass, but increased fasting glucose / reduced insulin sensitivity and no functional/strength benefit

  • Tesamorelin Phase 3 pooled analysis2010

    ~15% reduction in visceral adipose tissue vs placebo in HIV lipodystrophy (basis for that drug's approval)